Tau Aggregate Ligands for Alzheimer's Detection Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ligands are inadequate for specifically detecting tau deposits in neurodegenerative diseases like Alzheimer's, as they often fail to distinguish between different morphotypes of Aβ and tau aggregates, limiting accurate assessment and diagnosis.
Innovation Solution
Development of compounds of formula (I) with specific structural features that selectively target tau deposits, allowing for enhanced visualization and detection of tau pathology in Alzheimer's disease, including the use of radioisotopes for diagnostic imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional ligands (Congo Red, thioflavins) are used to detect protein aggregates, then general detection capability is achieved, but specificity for tau deposits is lost
Solution Approach 1:
The patent applies local quality by designing ligands with specific structural features (planar aromatic systems with particular substituents) that are optimized for binding to tau aggregates. The ligand structure contains specific functional groups and molecular arrangements that create localized binding pockets matching the unique structural characteristics of tau fibrils, thereby achieving tau-specific detection while maintaining the ability to detect other aggregates through structural variations in the ligand family.
Solution Approach 2:
The patent employs parameter changes by systematically modifying ligand structures (changing aromatic ring substitutions, linker lengths, and functional groups) to tune binding affinity and specificity. By adjusting these molecular parameters, the ligands achieve optimal selectivity for tau aggregates while preserving broad detection capability across different aggregate morphotypes through controlled structural diversity.
2Measurement precision
If ligands are designed for high selectivity toward tau deposits, then diagnostic accuracy is improved, but ability to detect other aggregate morphotypes is reduced
Solution Approach 1:
The patent achieves universality by creating a ligand platform where a core structural framework provides tau-specific binding capability, while modular substituents and side chains can be adjusted to extend detection range. The fundamental planar aromatic system with characteristic spacing maintains tau selectivity, whereas variations in peripheral groups enable adaptation to detect different aggregate morphotypes, making the ligand family both specific and versatile.
3Illumination intensity
If existing ligands are used for imaging, then visualization of protein aggregates is achieved, but differentiation between Aβ and tau aggregates is not possible
Solution Approach 1:
The patent applies color changes by incorporating fluorophores with distinct spectral properties into the ligand structure. Different ligand variants emit at different wavelengths or exhibit different fluorescence intensities when bound to tau versus Aβ aggregates, enabling optical differentiation. The molecular structure includes chromophoric groups whose emission characteristics change based on the specific aggregate type bound, providing both visualization and identification capabilities simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate high selectivity and affinity for tau deposits, potentially improving diagnostic accuracy and monitoring of disease progression in Alzheimer's and other tauopathies.
Implementation Method 1
compounds of formula (I) with specific structural features that selectively target tau deposits, allowing for enhanced visualization and detection of tau pathology
Data Source
AI summary
The invention provides compounds of formula (I) and compositions comprising compounds of formula (I). The invention further provides uses of the compounds of formula (I) and compositions comprising compounds of formula (I), including the use of such compounds for the detection of tau deposits, and the use of such compounds and compositions as diagnostic agents in the diagnosis or monitoring of the progression of a disease or disorder such as Alzheimer's disease or corticobasal degeneration, or for the prevention or treatment of a disease or disorder such as Alzheimer's disease or corticobasal degeneration.